The role of protein kinase C-alpha (PKC-α) in melanoma
The role of protein kinase C-alpha (PKC-α) in melanoma
复制标题
DOI：
10.1097/00008390-200404000-00002
复制
发表时间：
2004-04-01
影响因子：
2.2
通讯作者：
Sundell, KL
中科院分区：
文献类型：
--
作者：
Lahn, MM;Sundell, KL
在20世纪80年代，蛋白激酶C（PKC）被确定为皮肤肿瘤发生的一个促成因素。由于专门针对PKC的药物已经上市，本综述的目的是评估PKC，特别是PKC-α在黑色素瘤或其他皮肤癌中的作用。我们回顾和总结了已发表的研究，研究PKC-α在黑色素瘤或其他皮肤癌的发展中的作用。迄今为止，大多数研究都是基于细胞培养的。在黑色素瘤模型中，PKC-α活化通常与肿瘤细胞增殖增加、侵袭性和分化降低相关，这表明PKC-α抑制剂，如阿匹诺卡森（一种针对PKC-α的反义寡核苷酸）可能适用于治疗皮肤恶性肿瘤。由于选择性或特异性PKC-α抑制剂（包括aprinocarsen）的最新进展，越来越需要进行进一步的转化研究，特别是在黑色素瘤患者中，以确定可能从PKC-α靶向治疗中获益最多的患者人群。
In the 1980s, protein kinase C (PKC) was identified as a contributing factor in skin tumorigenesis. As drugs targeting specifically PKC have become available, the intent of this review was to assess the role of PKC, in particular of PKC-alpha in melanoma or other skin cancers. We reviewed and summarized published studies examining the role of PKC-alpha in the development of melanoma or other skin cancers. Most studies to date have been cell-culture based. In models of melanoma, PKC-alpha activation is typically associated with increased tumour cell proliferation, invasiveness and decreased differentiation, suggesting that PKC-alpha inhibitors, such as aprinocarsen, an antisense oligonucleotide directed against PKC-alpha, may be appropriate in the treatment of skin malignancies. Because of the recent developments on selective or specific PKC-alpha inhibitors, including aprinocarsen, there is a growing need to conduct further translational research, especially in melanoma patients, to identify the patient population that might benefit most from PKC-alpha targeted therapy.